A Phase 3 interventional study of Secukinumab and Ustekinumab in Plaque Psoriasis, sponsored by Novartis Pharmaceuticals. Completed at 155 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-09.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing secukinumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. secukinumab · Psoriasis.
Among the 54 studies testing secukinumab in Psoriasis, this one is the 4th largest by enrollment, is one of 4 that started in 2016, is one of 24 in phase 3, and was the 32nd registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →5 of the 54 studies testing secukinumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:
University Hospital, Ghent · Sites in Belgium
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Healthy volunteers
University of Athens · Sites in Greece
Ages 18–80 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Singapore General Hospital · Sites in Singapore
Ages 22–90
By country, each count listing its studies:
secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 24 · Phase 4 17
First in 2007; this study’s year is marked. 4 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,114 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 124 across the 54 interventional studies. Of the 46 that completed or were terminated, 38 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 54 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
68 studies in Psoriasis by Novartis: 3 open now, 4 under way, none of them phase 3. Of 61 finished, 41 (67%) have results posted.
Among the 68 studies in Psoriasis by Novartis, this one is the 4th largest by enrollment of the 53 interventional ones that give a count, is one of 4 that started in 2016, is one of 30 in phase 3, and was the 40th registered.
Novartis’s Psoriasis studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 54 studies testing secukinumab in Psoriasis, from their registry updates:
Among Novartis’s 68 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Demonstrate superiority of secukinumab over ustekinumab in treatment of moderate to severe plaque psoriasis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Moderate to severe plaque psoriasis as defined at randomization by:
Candidate for systemic therapy, defined as having psoriasis inadequately controlled by:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Secukinumab
Drug: Secukinumab
Ustekinumab
Drug: Ustekinumab
300mg, s.c. at randomization, Weeks 1, 2 and 3 and thereafter 4-weekly till Week 48
Per approved label, 45 mg or 90 mg s.c. based on subject weight (at randomization visit) to be administered at randomization, Week 4, 16, 28 and 40. At other timepoints subjects will receive placebo injections.
Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 12
Number of participants who achieved ≥ 90% reduction in PASI compared to baseline. Logistic regression analysis of PASI 90 response at Week 12 PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, upper limbs, trunk, lower limbs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of body region(head: 0.1, upper limbs: 0.2, trunk: 0.3, lower limbs: 0.4).
Time frame: Week 12
Participants With IGA Mod 2011 0 or 1 at Week 12
Investigator's Global Assessment uses a scale (IGA mod 2011) that rates disease from a score of 0 (clear skin) to 4 (severe disease)
Time frame: Week 12
Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 12
Number of participants who achieved ≥ 75% reduction in PASI at Week 12 compared to baseline.
Time frame: Week 12
Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 4
Number of participants who achieved ≥ 75% reduction in PASI at Week 4 compared to baseline.
Time frame: Week 4
Participants Who Achieved Psoriasis Area and Severity Index (PASI) 100 Response at Week 16
Number of participants who achieved 100% reduction in PASI at Week 16 compared to baseline.
Time frame: Week 16
Participants With IGA Mod 2011 0 or 1 at 16 Weeks
Investigator's Global Assessment uses a scale (IGA mod 2011) that rates disease from a score of 0 (clear skin) to 4 (severe disease)
Time frame: Week 16
Participants Who Achieved Psoriasis Area and Severity Index (PASI) 100 Response at Week 12
Number of participants who achieved 100% reduction in PASI at Week 12 compared to baseline.
Time frame: Week 12
Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 16
Number of participants who achieved ≥ 75% reduction in PASI at Week 16 compared to baseline.
Time frame: Week 16
Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 16
Number of participants who achieved ≥ 90% reduction in PASI at Week 16 compared to baseline.
Time frame: Week 16
Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 52
Number of participants who achieved ≥ 90% reduction in PASI at Week 52 compared to baseline.
Time frame: Week 52
Overall, 1353 patients were screened of which 1102 patients completed the Screening phase; 251 patients were screen failures
| Milestone | Secukinumab 300mg (2 x 150 mg) | Ustekinumab 2 x 45mg or 90mg |
|---|---|---|
| Started | 550 | 552 |
| Completed | 489 | 488 |
| Not completed | 61 | 64 |
| Withdrew: Adverse event | 17 | 9 |
| Withdrew: Lack of efficacy | 4 | 9 |
| Withdrew: Lost to follow-up | 13 | 12 |
| Withdrew: Noncompliance with treatment | 0 | 2 |
| Withdrew: Physician decision | 1 | 7 |
| Withdrew: Pregnancy | 1 | 2 |
| Withdrew: Protocol violation | 3 | 3 |
| Withdrew: Withdrawal by subject | 20 | 19 |
| Withdrew: Death | 2 | 0 |
| Withdrew: New therapy for study indication | 0 | 1 |
Number of participants who achieved ≥ 90% reduction in PASI compared to baseline. Logistic regression analysis of PASI 90 response at Week 12 PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, upper limbs, trunk, lower limbs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of body region(head: 0.1, upper limbs: 0.2, trunk: 0.3, lower limbs: 0.4).
| Participants | Secukinumab 300mg (2 x 150 mg) | Ustekinumab 2 x 45mg or 90mg |
|---|---|---|
| Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 12 | 366 | 265 |
Investigator's Global Assessment uses a scale (IGA mod 2011) that rates disease from a score of 0 (clear skin) to 4 (severe disease)
| Participants | Secukinumab 300mg (2 x 150 mg) | Ustekinumab 2 x 45mg or 90mg |
|---|---|---|
| Participants With IGA Mod 2011 0 or 1 at Week 12 | 397 | 306 |
Number of participants who achieved ≥ 75% reduction in PASI at Week 12 compared to baseline.
| Participants | Secukinumab 300mg (2 x 150 mg) | Ustekinumab 2 x 45mg or 90mg |
|---|---|---|
| Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 12 | 484 | 409 |
Number of participants who achieved ≥ 75% reduction in PASI at Week 4 compared to baseline.
| Participants | Secukinumab 300mg (2 x 150 mg) | Ustekinumab 2 x 45mg or 90mg |
|---|---|---|
| Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 4 | 221 | 90 |
Number of participants who achieved 100% reduction in PASI at Week 16 compared to baseline.
| Participants | Secukinumab 300mg (2 x 150 mg) | Ustekinumab 2 x 45mg or 90mg |
|---|---|---|
| Participants Who Achieved Psoriasis Area and Severity Index (PASI) 100 Response at Week 16 | 250 | 147 |
Investigator's Global Assessment uses a scale (IGA mod 2011) that rates disease from a score of 0 (clear skin) to 4 (severe disease)
| Participants | Secukinumab 300mg (2 x 150 mg) | Ustekinumab 2 x 45mg or 90mg |
|---|---|---|
| Participants With IGA Mod 2011 0 or 1 at 16 Weeks | 432 | 326 |
Number of participants who achieved 100% reduction in PASI at Week 12 compared to baseline.
| Participants | Secukinumab 300mg (2 x 150 mg) | Ustekinumab 2 x 45mg or 90mg |
|---|---|---|
| Participants Who Achieved Psoriasis Area and Severity Index (PASI) 100 Response at Week 12 | 210 | 111 |
Number of participants who achieved ≥ 75% reduction in PASI at Week 16 compared to baseline.
| Participants | Secukinumab 300mg (2 x 150 mg) | Ustekinumab 2 x 45mg or 90mg |
|---|---|---|
| Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 16 | 506 | 441 |
Number of participants who achieved ≥ 90% reduction in PASI at Week 16 compared to baseline.
| Participants | Secukinumab 300mg (2 x 150 mg) | Ustekinumab 2 x 45mg or 90mg |
|---|---|---|
| Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 16 | 423 | 299 |
Number of participants who achieved ≥ 90% reduction in PASI at Week 52 compared to baseline.
| Participants | Secukinumab 300mg (2 x 150 mg) | Ustekinumab 2 x 45mg or 90mg |
|---|---|---|
| Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 52 | 402 | 330 |
Collected over AEs and SAEs were collected for the maximum duration of treatment and follow up for a participant per protocol for approximately 52 months. All cause mortality (deaths) was collected from First Patient First Visit (FPFV) to Last Patient Last Visit (LPLV) up to a maximum of 52 weeks. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AIN457 300 mg | 2/550 (0.4%) | 29/550 (5.3%) | 216/550 (39.3%) |
| UST 45/90 mg | 0/552 (0%) | 21/552 (3.8%) | 229/552 (41.5%) |
| All Patients | 2/1,102 (0.2%) | 50/1,102 (4.5%) | 445/1,102 (40.4%) |
| Event | AIN457 300 mg | UST 45/90 mg | All Patients |
|---|---|---|---|
| Atrial fibrillationCardiac disorders | 3/550 | 0/552 | 3/1102 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 3/550 | 0/552 | 3/1102 |
| Ventricular tachycardiaCardiac disorders | 2/550 | 0/552 | 2/1102 |
| Dengue feverInfections and infestations | 2/550 | 0/552 | 2/1102 |
| Deep vein thrombosisVascular disorders | 2/550 | 1/552 | 3/1102 |
| CellulitisInfections and infestations | 1/550 | 2/552 | 3/1102 |
| LymphadenopathyBlood and lymphatic system disorders | 1/550 | 0/552 | 1/1102 |
| Angina pectorisCardiac disorders | 1/550 | 0/552 | 1/1102 |
| Myocardial ischaemiaCardiac disorders | 1/550 | 0/552 | 1/1102 |
| Anal fissureGastrointestinal disorders | 1/550 | 0/552 | 1/1102 |
| Event | AIN457 300 mg | UST 45/90 mg | All Patients |
|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 49/550 | 61/552 | 110/1102 |
| NasopharyngitisInfections and infestations | 55/550 | 54/552 | 109/1102 |
| DiarrhoeaGastrointestinal disorders | 26/550 | 24/552 | 50/1102 |
| HeadacheNervous system disorders | 26/550 | 25/552 | 51/1102 |
| SinusitisInfections and infestations | 25/550 | 18/552 | 43/1102 |
| HypertensionVascular disorders | 17/550 | 22/552 | 39/1102 |
| Back painMusculoskeletal and connective tissue disorders | 14/550 | 20/552 | 34/1102 |
| BronchitisInfections and infestations | 8/550 | 18/552 | 26/1102 |
| PruritusSkin and subcutaneous tissue disorders | 12/550 | 18/552 | 30/1102 |
| CoughRespiratory, thoracic and mediastinal disorders | 17/550 | 16/552 | 33/1102 |
| Age, Continuous(years) | Secukinumab 300mg (2 x 150 mg) | Ustekinumab 2 x 45mg or 90mg | Total |
|---|---|---|---|
| Mean | 45.4 ± 14.09 | 45.3 ± 14.16 | 45.4 ± 14.12 |
| Age, Customized(Participants) | Secukinumab 300mg (2 x 150 mg) | Ustekinumab 2 x 45mg or 90mg | Total |
|---|---|---|---|
| <65 years | 488 | 494 | 982 |
| >=65 years and <75 years | 60 | 48 | 108 |
| >=75 years | 2 | 10 | 12 |
| Sex: Female, Male(Participants) | Secukinumab 300mg (2 x 150 mg) | Ustekinumab 2 x 45mg or 90mg | Total |
|---|---|---|---|
| Female | 194 | 176 | 370 |
| Male | 356 | 376 | 732 |
| Race/Ethnicity, Customized(Participants) | Secukinumab 300mg (2 x 150 mg) | Ustekinumab 2 x 45mg or 90mg | Total |
|---|---|---|---|
| Caucasian | 416 | 410 | 826 |
| Black | 21 | 24 | 45 |
| Asian | 60 | 57 | 117 |
| Native American | 34 | 41 | 75 |
| Pacific Islander | 1 | 5 | 6 |
| Unknown | 4 | 2 | 6 |
| Other | 14 | 13 | 27 |
Showing the first 100 of 155 sites across 11 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Jun 2016 to primary completion in Jul 2018, 24 months.
Results were first posted in Jul 2019, 1 year after primary completion.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 24 months is above that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Secukinumab